| | Antimicrobial susceptibility testing of Campylobacter jejuni: a comparison between Etest and agar dilution methodAbstract The susceptibility of Campylobacter jejuni strains (n = 50) against nine antimicrobials were determined in comparison with Etest (AB BIODISK, Solna, Sweden) and agar dilution method to further investigate the correlation between the two methods. All the strains were isolated from stool samples of patients with diarrhea in 1998 and found to be highly susceptible (>84%) to ampicillin, tetracycline, gentamicin, chloramphenicol, ciprofloxacin and erythromycin. The essential agreement between two methods was 66.6% (±1 log2 dilution) and 85.5% (±2 log2 dilution). The agreement of susceptibility categories was higher at 94.4%.
1. Introduction  Campylobacter jejuni is one of the most frequent causes of bacterial diarrhea in developing countries (Nachamkin, 1995). Because of the self limiting nature of Campylobacter infections, antibiotic treatment is often not necessary and antibiotic susceptibility testing of C. jejuni is usually not performed in clinical laboratories (Blaser, 2000). Agar dilution is the recommended method for susceptibility testing (Tenover et al., 1992). Etest (AB BIODISK, Solna, Sweden) has been demonstrated to be an easy alternative method for Campylobacter spp, as it is for other bacteria Baker 1992, Tenover et al 1992. In this study, we determined the susceptibility of C. jejuni strains against nine antimicrobial agents in a comparative study with Etest and standard agar dilution method to further investigate the correlation between these methods. The 50 strains used have been isolated and identified from stool samples of patients with diarrhea between April and October 1998 using standard microbiologic methods (Nachamkin, 1995). The strains were stored in tryptic soy broth with 20% glycerol at −70°C until analyzed. The control strains used were Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. Ampicillin, ampicillin-sulbactam (2/1 ratio), clarithromycin, tetracycline, gentamicin, azithromycin, chloramphenicol, ciprofloxacin and erythromycin were the agents used for susceptibility testing. The antimicrobial powders were obtained from the manufacturers. Etest strips were purchased from AB BIODISK. The inoculum was prepared from 48 h growth of C. jejuni on 5–7% horse blood agar. The colonies were suspended in Mueller Hinton broth (Oxoid, Basingtoke, UK) to achieve a turbidity equivalent to a standard MacFarland of 0.5. The determination of MICs by agar dilution was performed according to NCCLS guidelines using Mueller Hinton agar (Oxoid, Basingtoke, UK) supplemented with 5–7% horse blood and the breakpoints given for organisms other than Hemophilus, Neisseria gonorrhoeae and Streptococcus pneumoniae were used (NCCLS, 2000 and 2002). Etest was set up on the same agar according to the manufacturer’s instructions Brown and Brown 1991, Huang et al 1992, Funke et al 1993. Plates were incubated at 37°C in candle jar for 24 h. The incubation time was extended to 48 h for agar dilution test if necessary. C. jejuni strains were found to be highly susceptible to the antibiotics tested. The highest resistance rate was seen with tetracycline and ciprofloxacin; 12% by Etest and 16% by agar dilution for tetracycline and 14% for ciprofloxacin by both methods. For most of the strains (13/50), lower MIC values were obtained with Etest (Table 1). The ranges, MIC50, MIC90 and the resistance rates are outlined in Table 1. The agreement between the two methods analyzed as log2 dilution differences is presented in Table 2. The discrepancies between the methods evaluated as minor, major and very major errors. The highest discrepancy between Etest and agar dilution (>2 dilution) were seen with chloramphenicol (48%), ampicillin-sulbactam (44%), clarithromycin and tetracycline (40%). For erythromycin which is considered to be the drug of choice for Campylobacter infections, Etest results were outside the accepted ranges (±2 dilution) for 34% of the strains tested. The essential agreements between two methods were 66.6% (±1 dilution) and 85.5% (±2 dilution). The agreement of susceptibility categories were higher at 94.4%. There were no major and very major discrepancies. The minor discrepancy rates were 6% or less for all the agents tested except for erythromycin with 30% minor discrepancy. For the control strain, there was correlation between the two methods. The difference between the susceptibility percentages determined by each test were not statistically significant (P > 0.05) except for erythromycin which was 80% by Etest and 58% by agar dilution test: 11 strains susceptible by Etest were intermediate by agar dilution. The category interpretation of erythromycin results is considered as a problem when using current NCCLS (2002) breakpoints. | | |  | Antimicrobial agentsa | Methoda | MIC range (mg/L) | MIC50 (mg/L) | MIC90 (mg/L) | Resistance % |  |
 | AM | E | 0.064–32 | 2 | 8 | 2 |  |
 | | AD | 0.032–32 | 2 | 8 | 2 |  |
 | AB | E | 0.064–8 | 1 | 4 | 0 |  |
 | | AD | 0.064–8 | 2 | 8 | 0 |  |
 | EM | E | 0.032–4 | 0.25 | 1 | 0 |  |
 | | AD | 0.064–4 | 0.5 | 2 | 0 |  |
 | CH | E | 0.016–4 | 0.25 | 1 | 0 |  |
 | | AD | 0.064–16 | 0.5 | 2 | 2 |  |
 | AZ | E | 0.016–16 | 0.064 | 0.25 | 4 |  |
 | | AD | 0.032–32 | 0.125 | 0.25 | 4 |  |
 | GM | E | 0.016–16 | 0.5 | 2 | 2 |  |
 | | AD | 0.064–4 | 0.5 | 2 | 2 |  |
 | TC | E | 0.064–32 | 0.25 | 8 | 12 |  |
 | | AD | 0.032–256 | 0.25 | 16 | 16 |  |
 | CL | E | 0.25–8 | 1 | 4 | 0 |  |
 | | AD | 1–8 | 2 | 8 | 0 |  |
 | CI | E | 0.016–32 | 0.064 | 8 | 14 |  |
 | | AD | 0.016–32 | 0.125 | 8 | 14 |  | | | |
|
a
E, Etest; AD, Agar dilution; AB, Ampicillin-sulbactam; CH, Clarithromycin; AM, Ampicillin; EM, Erythromycin; GM, Gentamicin; AZ, Azithromycin; TC, Tetracycline; CL, Chloramphenicol; CI, Ciprofloxacin. |
| | |  | Antimicrobial agentsa | <−2 | −2 | −1 | 0 | +1 | +2 | >+2 | Out of accepted range (%) |  |
 | AM | 5 | 2 | 9 | 15 | 14 | 1 | 4 | 24 |  |
 | AB | 5 | 11 | 15 | 8 | 5 | - | 6 | 44 |  |
 | EM | 7 | 6 | 15 | 14 | 4 | 3 | 1 | 34 |  |
 | CH | 6 | 2 | 15 | 11 | 4 | 7 | 10 | 40 |  |
 | AZ | - | 3 | 26 | 13 | 6 | 1 | 1 | 10 |  |
 | GM | 4 | 5 | 17 | 11 | 8 | 3 | 2 | 28 |  |
 | TC | - | 9 | 10 | 11 | 9 | 4 | 7 | 40 |  |
 | CL | 4 | 19 | 15 | 7 | 4 | 1 | - | 48 |  |
 | CI | 4 | 5 | 16 | 15 | 3 | 2 | 10 | 32 |  |
 | All Agents | 35 | 63 | 136 | 105 | 57 | 22 | 41 | 33 |  | | | |
|
a
E, Etest; AD, Agar dilution; AB, Ampicillin-sulbactam; CH, Clarithromycin; AM, Ampicillin; EM, Erythromycin; GM, Gentamicin; AZ, Azithromycin; TC, Tetracycline; CL, Chloramphenicol; CI, Ciprofloxacin. |
In this group of relatively small number of Campylobacter spp. strains collected from a single geographic area, there was acceptable agreement between Etest and the agar dilution for susceptibility categorization. Since Etest is neither dependent on special equipment nor time-consuming, it may be a useful alternative for susceptibility testing of Campylobacter spp. in clinical laboratories and this finding is in parallel with a study in Taiwan (Li et al., 1998). References  Baker 1992.
1.
Baker CN.
The Etest and Campylobacter jejuni.
Diagn Microbiol Infect Dis. 1992;15:469–472. MEDLINE |
CrossRef
Blaser 2000.
2.
Blaser MJ.
Campylobacter jejuni and related species.
In:
Mandell GL, Bennett JE, Dolin R editor. Principles and practise of infectious diseases. Pennsylvania: Churchill Livingstone; 2000;p. 2276–2285. Brown and Brown 1991.
3.
Brown DFJ, Brown L.
Evaluation of the Etest, a novel method of quantifying antimicrobial activity.
J Antimicrob Chemother. 1991;27:185–190. MEDLINE Funke et al 1993.
4.
Funke G, Hottenstein JL, Altweg M.
The Etest for antimicrobial susceptibility testing of clinical Campylobacter jejuni and Campylobacter coli isolates.
Med Microbiol Lett. 1993;2:168–175. Huang et al 1992.
5.
Huang MB, Baker CN, Banerjee S, Tenover FC.
Accuracy of the Etest for determining antimicrobial susceptibilities of Staphylococci, Enterococci, Campylobacter jejuni and Gram negative bacteria resistant to antimicrobial agents.
J Clin Microbiol. 1992;30:3243–3248. MEDLINE Li et al 1998.
6.
Li CC, Chiu CH, Wu JL, Huang YC, Lin Ty.
Antimicrobial susceptibilities of C. jejuni and C. coli by using Etest in Taiwan.
Scand J Infect Dis. 1998;30:39–42. MEDLINE |
CrossRef
Nachamkin 1995.
7.
Nachamkin I.
Campylobacter and arcobacter.
In:
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH editor. Manual of clinical microbiology. Washington DC: American Society for Microbiology; 1995;p. 483–491. National Committee for Clinical Laboratory Standards (NCCLS) 2000.
8.
National Committee for Clinical Laboratory Standards (NCCLS).
Methods for dilution susceptibility tests for bacteria that grow aerobically.
In: Approved standard M7-A5. Fourth Edition. Villanova, Pa: NCCLS; 2000;. National Committee for Laboratory Standards (NCCLS) 2002.
9.
National Committee for Laboratory Standards (NCCLS).
Minimum inhibitory concentration interpretive standards of three categories of susceptibility for organisms other than Haemophilus, Neisseria gonorrhoeae and Streptococcus pneumoniae.
In: Approved standard M100-S12. Villanova, Pa: NCCLS; 2002;. Tenover et al 1992.
10.
Tenover FC, Baker CN, Fennell CL, et al.
Antimicrobial resistanceCampylobacter species.
In:
Nachamkin I, Blaser MJ, Tompkins LS editor. Campylobacter jejuni, current status and future trends. Washington DC: American Society for Microbiology; 1992;p. 66–74. a Refik Saydam Hygiene Center, Department of Microbiology and Clinical Microbiology, Ankara, Turkey b Hacettepe University, Department of Internal Medicine, Section of Infectious Diseases, Ankara, Turkey c Hacettepe University, Ihsan Dogramaci Children Hospital, Clinical Microbiology Laboratory, Ankara, Turkey Corresponding author. Tel.: +90-312-3111271; fax: +90-312-3104179.
PII: S0732-8893(02)00496-0 doi:10.1016/S0732-8893(02)00496-0 © 2003 Elsevier Science Inc. All rights reserved. | |
|